摘要
目的探讨黄葵胶囊联合缬沙坦治疗糖尿病肾病临床疗效。方法方便选取该院2014年5月—2016年5月期间收治的86例糖尿病肾病患者,依据随机法划分为参照组与研究组各43例。参照组43例患者给予缬沙坦等常规治疗,研究组43例患者在此基础上加用黄葵胶囊进行治疗。对两组患者临床指标及临床疗效进行比较。结果治疗后研究组TC为(4.7±0.4)mmol/L,明显低于参照组的(5.7±0.2)mmol/L,差异有统计学意义(t=14.662 9,P=0.000 0<0.05);治疗后研究组TG为(2±0.8)mmol/L,明显低于参照组的(2.6±0.5)mmol/L,差异有统计学意义(t=4.170 5,P=0.000 1<0.05);治疗后研究组UAER为(89.25±18.2)μg/min,明显低于参照组的(113.3±20.7)μg/min,差异有统计学意义(t=5.716 1,P=0.000 0<0.05);研究组治疗后总有效率为93.0%,明显高于参照组的67.4%,差异有统计学意义(χ~2=8.871 3,P=0.002 9<0.05)。结论对糖尿病肾病患者应用黄葵胶囊联合缬沙坦治疗可取得良好的效果,且不良反应少,值得推广。
Objective To discuss the clinical curative effect of Abelmosk capsule and valsartan in treatment of diabetic nephropathy. Methods 86 cases of patients with diabetic nephropathy admitted and treated in our hospital from May 2014 to May 2016 were convenient selected and randomly divided into two groups with 43 cases in each, the control group adopted the routine treatment of valsartan, while the research group adopted the f abelmosk capsule and valsartan treatment, and the clinical index and clinical curative effect were compared between the two groups. Results The TC in the research group after treatment was obviously lower than that in the control group[(4.7±0.4)mmol/L vs(5.7±0.2)mmol/L], and the difference was statistically significant(t=14.662 9,P=0.000 0<0.05), after treatment, the TG in the research group after treatment was obviously lower than that in the control group[(2±0.8)mmol/L vs(2.6±0.5)mmol/L], and the difference was statistically significant(t=4.170 5,P=0.000 1<0.05), after treatment, the UAER in the research group was obviously lower than that in the control group, [(89.25±18.2)μg/min vs(113.3±20.7)μg/min], and the difference was statistically significant(t=5.716 1,P =0.000 0 <0.05), and the total treatment effective rate in the research group was obviously higher than that in the control group(93.0% vs 67.4%),and the difference was statistically significant(χ~2=8.871 3,P=0.002 9<0.05). Conclusion The effect of abelmosk capsule and valsartan in treatment of diabetic nephropathy is good with few adverse reactions, which is worth promotion.
作者
李英兰
LI Ying-lan(Department of Medicine, Yucheng Hospital of Traditional Chinese Medicine, Yucheng, Shandong Province, 251200 China)
出处
《中外医疗》
2017年第11期130-131,134,共3页
China & Foreign Medical Treatment
关键词
黄葵胶囊
缬沙坦
糖尿病肾病
Abelmosk capsule
Valsartan
Diabetic nephropathy
